DNASE2

Deoxyribonuclease 2 lysosomal

Score: 0.528 Price: $0.53 Low Druggability Status: active Wiki: DNASE2

🧠 Neurodegeneration

HYPOTHESES

1

PAPERS

22

KG EDGES

23

DEBATES

1

3D Protein Structure

🧬 DNASE2 — PDB 1BYR Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Druggability & Clinical Context

Druggability

Low

Score: 0.30

Clinical Stage

Phase I

Target Class

Enzyme

Safety

0.60

Druggability Analysis

Drug Development0.15

Structural Tractability0.30

Target Class0.85

Safety Profile0.60

Key Metrics

PDB Structures:

0

Known Drugs:

1

Approved:

0

In Clinical Trials:

0

Drug Pipeline (1 compounds)

Druggability Rationale: DNASE2 (Deoxyribonuclease II) demonstrates low druggability due to its intracellular lysosomal localization and complex enzymatic mechanism. While the AlphaFold structural prediction provides insights, the lack of specific small molecule inhibitors and no current clinical trials suggest significant challenges in developing targeted therapeutic interventions for neurodegeneration. The enzyme's complex role in DNA degradation and potential inflammatory processes requires more fundamental research to establish viable drugging strategies.

Mechanism: Small molecule inhibitor or activator of nuclease activity

Drug Pipeline (1 compounds)

Known Drugs:

No specific inhibitors (research) — Lysosomal DNase — enzyme augmentation approaches under study

Structural Data:

PDB —AlphaFold ✓Cryo-EM —

UniProt: O00115

🧬 3D Protein Structure

🧬 DNASE2 — PDB 1BYR Click to expand interactive 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Selectivity & Safety Considerations

DNASE2 selectivity challenges include potential cross-reactivity with other lysosomal and cytoplasmic nucleases (DNASE1, DNASE1L3); however, its lysosomal compartmentalization and unique immunoregulatory role in DNA sensing may enable selective targeting. Isoform selectivity is less concerning as DNASE2 has limited known variants, but off-target DNase inhibition could impair normal DNA degradation pathways.

3D Protein Structure (AlphaFold)

Open full viewer

AlphaFold predicted structure available for O00115

View AlphaFold Structure

Clinical Trials (8)

Relevant trials from ClinicalTrials.gov

Active

1

Completed

7

Total Enrollment

860

By Phase

NA: 5 · PHASE1: 1 · PHASE2: 1 · Unknown: 1

Anger Control Training for Youth With Tourette Syndrome Completed

NA NCT00486551 n=26

Tourette Syndrome, Chronic Tic Disorder, Oppositional Defiant Disorder

Interventions: Anger control training

Sponsor: Yale University | Started: 2001-08

Adaptive vs. Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease Recruiting

NA NCT06909045 n=130

Deep Brain Stimulation, Parkinson Disease

Interventions: Adaptive DBS, Continue DBS

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC | Started: 2026-01-27

Expiratory Muscle Training in Patients With Parkinson's Disease Completed

PHASE1 NCT00843739 n=90

Parkinson's Disease

Interventions: EMST - Active Treatment, sham EMST

Sponsor: University of Florida | Started: 2004-01

Study of the Follow-up of Stroke Treated With Anticoagulants Completed

Unknown NCT03292575 n=441

Stroke

Interventions: Anticoagulants

Sponsor: Centre Hospitalier Universitaire Dijon | Started: 2016-01

Early Detection and Prevention of Mild Cognitive Impairment Due to Cerebrovascular Disease Completed

NA NCT01924312 n=80

Cerebrovascular Disease, Mild Cognitive Impairment

Interventions: Heart Health Intervention

Sponsor: Gregory Jicha, 323-5550 | Started: 2013-05

Effects of Modern Board Games on Well Being in Older Adults Completed

NA NCT06306365 n=35

Executive Functions

Interventions: Modern board game-based learning

Sponsor: European University Miguel de Cervantes | Started: 2024-02-07

Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol Completed

NA NCT02260167 n=25

Alzheimer's Disease, Dementia

Interventions: A mix of natural treatments and medicati

Sponsor: Practitioners Alliance Network | Started: 2014-09

A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2) Completed

PHASE2 NCT03987295 n=33

Frontotemporal Dementia

Interventions: AL001

Sponsor: Alector Inc. | Started: 2019-09-27

Linked Hypotheses (0)

No linked hypotheses

Linked Experiments (0)

No linked experiments

Scoring Dimensions

Knowledge Graph (20)

co discussed (15)

MMP9→DNASE2SLC7A11→DNASE2CGAS→DNASE2AQP4→DNASE2CD38→DNASE2

▸ Show 10 more

C1Q→DNASE2NAMPT→DNASE2GPX4→DNASE2PLA2G6→DNASE2IL1B→DNASE2MMP2→DNASE2DNASE2→STING1DNASE2→C3DNASE2→PLA2G4ADNASE2→AQP4

interacts with (4)

CGAS→DNASE2STING1→DNASE2DNASE2→CGASDNASE2→STING1

participates in (1)

DNASE2→Mitochondrial dynamics / bioenergetics

Debate History (1)

Should DNASE2 (Deoxyribonuclease 2 lysosomal) be prioritized as a therapeutic ta2026-04-22